Richard Daniell - Feb 7, 2023 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Exec. VP, European Commercial
Signature
/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell
Stock symbol
TEVA
Transactions as of
Feb 7, 2023
Transactions value $
$0
Form type
4
Date filed
2/9/2023, 06:01 AM
Previous filing
Mar 8, 2022
Next filing
Mar 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award $0 +50.2K $0.00 50.2K Feb 7, 2023 Ordinary Shares 50.2K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2 Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.